--- title: "Pre-market hot trades in US stocks: Waton Financial up 11.76% in pre-market; U-BX Tech down 8.06% in pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/286559443.md" description: "Waton Financial pre-market up 11.76%; U-BX Tech pre-market down 8.06%; HCW Biologics pre-market up 175.28%; Dreamland pre-market up 117.50%; Murano Global BV pre-market up 68.35%" datetime: "2026-05-15T11:47:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286559443.md) - [en](https://longbridge.com/en/news/286559443.md) - [zh-HK](https://longbridge.com/zh-HK/news/286559443.md) --- # Pre-market hot trades in US stocks: Waton Financial up 11.76% in pre-market; U-BX Tech down 8.06% in pre-market **Pre-market Hot Trades in US Stocks** Waton Financial, up 11.76% in pre-market, has no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. U-BX Tech, down 8.06% in pre-market, has no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. **Top Gainers in Pre-market US Stocks** HCW Biologics is up 175.28% in pre-market. Based on recent news, 1. On May 14, HCW Biologics announced that its candidate drug HCW11-040 is in IND-enabled research to prevent bronchopulmonary dysplasia (BPD), with research expected to be completed in the second half of 2027 and an IND application submitted. This finding significantly boosts market confidence in the company's future development, driving the stock price sharply higher. 2. On May 14, HCW Biologics released its business highlights and financial performance for Q1 2026. The company reported a basic earnings per share of $0.37, exceeding market expectations, further enhancing investor confidence. 3. On May 14, analysts rated HCW Biologics as "Buy," and Wall Street's 12-month median target price for the company is $2.00, approximately 472.4% higher than the closing price of $0.35 on May 13. This optimistic analyst expectation also provides strong support for the stock price. The biotechnology sector has performed strongly recently, and investor sentiment is high. Dreamland is up 117.50% in pre-market. Based on recent news, 1. On May 12, Dreamland announced that its subsidiary Trendic International signed a memorandum of understanding with LinkFung Innovation to explore the development, implementation, and deployment of a comprehensive AI-driven smart image library platform. This news propelled the stock price upward. 2. On May 13, Dreamland's stock price surged 126.92%, closing at $2.36, with a trading volume of approximately $219 million. Market sentiment is high, with significant capital inflow, and technical indicators show bullish signals. 3. On May 14, technical analysis showed that Dreamland's RSI reached 97.75, indicating that the stock price is extremely overbought, and a sharp correction may occur in the short term. The stock price is significantly above key moving averages, and the market is optimistic about its future performance. There have been no major sector-specific positive developments in the film and entertainment industry recently. Murano Global BV is up 68.35% in pre-market. Based on recent news, 1. On May 11, Murano Global Investments submitted an initial Form 3, appointing Oscar Jazmani Mendoza Escobar as Chief Financial Officer. This appointment is seen as a significant adjustment in the company's management, enhancing market confidence in the company's future development and driving a substantial increase in stock prices. 2. On May 11, Murano Global Investments submitted an initial Form 3, appointing Marcos Sacal Cohen as Chief Operating Officer and Director. This change in senior management was interpreted by the market as an enhancement of the company's operational capabilities, further boosting investor confidence. 3. On May 11, Murano Global Investments' Form 3 indicated that Director, CEO, and 10% shareholder Sacal Cababie Elias holds 69,152,609 shares of common stock. This information suggests that the company's executives are confident in the company's prospects, further driving up stock prices. The market reacted positively to the changes in the company's management, leading to a significant increase in stock prices ### Related Stocks - [WTF.US](https://longbridge.com/en/quote/WTF.US.md) - [UBXG.US](https://longbridge.com/en/quote/UBXG.US.md) - [HCWB.US](https://longbridge.com/en/quote/HCWB.US.md) - [TDIC.US](https://longbridge.com/en/quote/TDIC.US.md) - [MRNO.US](https://longbridge.com/en/quote/MRNO.US.md) ## Related News & Research - [Are Wall Street Analysts Predicting Brown-Forman Stock Will Climb or Sink?](https://longbridge.com/en/news/286932286.md) - [Entegris files Form 3 for CFO Nagesh Sukhi initial beneficial ownership statement](https://longbridge.com/en/news/286954887.md) - [TD Synnex Insider Sold Shares Worth $1,147,692, According to a Recent SEC Filing](https://longbridge.com/en/news/286872007.md) - [Elis: Disclosure of the number of shares forming the capital and of the total number of voting rights as of 30 04 2026](https://longbridge.com/en/news/286770212.md) - [Stock Of The Day: Is This The Bottom For Workday?](https://longbridge.com/en/news/286790632.md)